The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo Academic Article uri icon

Overview

MeSH Major

  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Urinary Bladder Neoplasms

abstract

  • Our data demonstrate that belinostat inhibits bladder cancer and supports the clinical evaluation of belinostat for the treatment of patients with superficial bladder cancer.

publication date

  • October 12, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2100044

Digital Object Identifier (DOI)

  • 10.1186/1479-5876-5-49

PubMed ID

  • 17935615

Additional Document Info

start page

  • 49

volume

  • 5